
|Videos|April 15, 2022
Single-Agent versus Combination Therapy in Metastatic Prostate Cancer
Author(s)Scott Tagawa, MD, MS, FACP, FASCO
Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
2
FDA Approves Novel Interchangeable Biosimilar for Pertuzumab in HER2+ Breast Cancer
3
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
4
How Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
5









































